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AbstrAct
Objective The aetiology of thoracic aortic aneurysm (TAA) 
is largely unknown, but inflammation is likely to play a 
central role in the pathogenesis. In this present study, we 
aim to investigate the complement receptors in TAA.
Methods Aortic tissue and blood from 31 patients with 
non- syndromic TAA undergoing thoracic aortic repair 
surgery were collected. Aortic tissue and blood from 36 
patients with atherosclerosis undergoing coronary artery 
bypass surgery or aortic valve replacement were collected 
and served as control material. The expression of the 
complement anaphylatoxin receptors C3aR1, C5aR1 and 
C5aR2 in aortic tissue were examined by quantitative 
RT- PCR and C5aR2 protein by immunohistochemistry. 
Colocalisation of C5aR2 to different cell types was 
analysed by immunofluorescence. Complement activation 
products C3bc and sC5b-9 were measured in plasma.
Results Compared with controls, TAA patients had 
substantial (73%) downregulated gene expression 
of C5aR2 as seen both at the mRNA (p=0.005) level 
and protein (p=0.03) level. In contrast, there were no 
differences in the expression of C3aR1 and C5aR1 
between the two groups. Immunofluorescence 
examination showed that C5aR2 was colocalised to 
macrophages and T cells in the aortic media. There were 
no differences in the degree of systemic complement 
activation between the two groups.
Conclusion Our findings suggest downregulation of 
the C5aR2, regarded to act mainly anti- inflammatory, 
in electively operated TAA as compared with non- 
aneurysmatic aortas of patients with aortic stenosis and/or 
coronary artery disease. This may tip the balance towards 
a relative increase in the inflammatory responses induced 
by C5aR1 and thus enhance the inflammatory processes 
in TAA.
IntROduCtIOn
Thoracic aortic aneurysm (TAA) is charac-
terised by progressive degradation of the 
aortic wall, increasing aortic diameter and 
increasing risk of lethal complications such as 
rupture and dissection, but the causes of TAA 
dilation are at present not fully understood.1 
Genetic factors are definitively of importance 
in syndromic aortic aneurysmatic disease (eg, 
Loeys- Dietz and Marphan syndrome) and 
can also contribute to non- syndromic TAA.2 
Key questions
What is already known about this subject?
 ► Thoracic aortic aneurysm (TAA) is characterised by 
progressive degradation of the aortic wall, increas-
ing aortic diameter and increasing risk of lethal 
complications such as rupture and dissection.
 ► The aetiology of TAA is largely unknown, but in-
flammation is likely to play central role in the 
pathogenesis.
What does this study add?
 ► The present study showed a marked highly specific 
downregulation of the anti- inflammatory C5aR2 in 
TAA patients both at the mRNA level and as protein 
immunostaining, without any changes in C3aR1 
and C5aR1, compared with atherosclerotic non- 
aneurysmatic controls.
 ► C5aR2 colocalised with T cells and macrophages 
in the media of patients with TAA. Protein immu-
nostaining data suggest that the downregulation of 
C5aR2 in TAA does not merely reflect downregula-
tion of the C5aR2 expressingT cells or macrophages.
 ► No systemic complement system activation in pa-
tients with TAA.
How might this impact on clinical practice?
 ► C5aR2 downregulation may tip the balance towards 
a relative increase in the inflammatory responses 
induced by C5aR1 and thus enhance the inflamma-
tory processes in TAA.
 ► These data have implications for understanding the 
pathophysiology of TAA, and probably pave the way 
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Table 1 Characteristics of controls and patients with 






Aortic diameter (cm)‡ 3.4±0.6 5.6±0.8 ***
EARD§ 3.6±0.2 3.6±0.2 ns
Men / Women 75 % / 25% 77 % / 23% ns
Age, y 67.4±9.1 62.8±11.6 ns
Weight, kg 84.0±16.0 88.3±18.1 ns
Height, cm 175±7 179±9 ns
Cardiovascular risk factors       
  Diabetes type 1/type 2 6 % / 22% 0 % / 6% ns
  Hyperlipidaemia 31% 13% ns
  Systolic blood pressure (mm Hg) 136±18 135±12 ns
  Diastolic blood pressure (mm Hg) 76±10 75±12 ns
Medical history       
  Heart failure 14% 13% ns
  Aortic stenosis 33% 39% ns
  Coronary artery disease 81% 10% ***
  Atherosclerosis of carotid arteries 11% 3% ns
  Peripheral vascular disease 8% 0% ns
  Atrial fibrillation 6% 16% ns
  Kidney disease (Creatinine >100) 14% 6% ns
Clinical chemistry (preoperative)       
  Haemoglobin (g/100 mL) 13.6±1.7 14.1±2.7 ns
  Thrombocytes (×10⁹/L) 240±49 243±73 ns
  Leucocytes (×10⁹/L) 7.4±2.2 7.2±1.9 ns
  C reactive protein (mg/L) 6.93±10.6 3.5±3.9 ns
Medication (preoperative)       
  ACE inhibitors 17% 26% ns
  Angiotensin receptor blockers 25% 29% ns
  Beta- blockers 67% 39% *
  Statins 72% 23% ***
  Aspirin 83% 29% ***
*p<0.05 versus non- aneurysmal aorta, ***p<0.0001 versus non- 
aneurysmal aorta.
†Data are mean±SD or % of total.
‡Aortic diameters were not available for 10/36 control patients.
§Estimated aortic root dimension (EARD) based on height, formula 
adapted from Devereux et al: 1.519+(age [yrs]*0.010)+(ht [cm]*0.010)−
(sex [1=M, 2=F]*0.247) SEE = EARD.39
Atherosclerosis is a well- established risk factor of abdom-
inal aortic aneurysms (AAA), but only a small proportion 
of patients with aortic atherosclerosis develop aneurysm, 
pointing towards overlapping as well as specific mecha-
nisms in these two conditions.3 Moreover, whereas ather-
osclerosis has been established as a risk factor in the 
development of AAA, its role in TAA is unclear.4 5
The complement system is a part of the innate immune 
system, and serves as a bridge between innate and adap-
tive immunity, as well as between inflammation and coag-
ulation,6 a cross- talk termed thromboinflammation.7 
Whereas the complement system is important in tissue 
homostasis and immune surveillance,8 overwhelming or 
persistent activation of complement may contribute to 
tissue destruction and chronic inflammation. Indeed, 
the complement system seems to play a pathogenic role 
in various inflammatory conditions such as sepsis9 10 and 
various autoimmune diseases.11 Enhanced complement 
activation seems also to play a pathogenic role in several 
cardiovascular diseases including atherosclerosis.12
C3a and C5a are small activation products of the 
complement cascade, frequently called anaphylatoxins, 
released when C3 and C5 are activated. They contribute 
to the regulation of local inflammatory responses, mainly 
by inflammatory effects, but seem also to have anti- 
inflammatory properties. Their effects are mainly medi-
ated through activation of complement receptors, a group 
of G protein- coupled receptors,13 14 termed C3aR, C5aR1 
and C5aR2. The complement receptor C5aR2, previously 
called C5L2, was discovered much later than the others. 
Thus, the function of this receptor is not fully elucidated 
and there has been controversies regarding its main func-
tion from being a scavenger receptor neutralising C5a to 
recent evidence suggesting that C5a/C5aR2 is signalling 
through mechanisms different from C5aR1.15 16 It has in 
fact gradually become evident that the C5aR2 is mainly 
an anti- inflammatory receptor.17 18
Although there is some data on complement expres-
sion in human AAA,19 data on the complement system 
in TAA is scarce. To elucidate a possible role for comple-
ment activation in the pathogenesis of TAA, we exam-
ined the expression of the complement anaphylatoxin 




Patients undergoing elective TAA repair surgery at the 
Department of Cardiothoracic Surgery, Oslo Univer-
sity Hospital, Oslo, Norway were included. Biopsies 
from 31 aneurysmal and 36 non- aneurysmal atheroscle-
rotic aortas (controls) were collected intraoperatively 
(table 1). Non- aneurysmal aortic samples were collected 
from patients undergoing coronary artery bypass grafting 
(CABG) or aortic valve replacement (AVR) surgery at the 
same department. The mean aortic diameters of aneu-
rysmal aortas were 5.6±0.8 cm compared with 3.4±0.6 in 
controls. Both patients with tricuspid and bicuspid aortic 
valves were included. Patients with aneurysms secondary 
to known genetic disease (e.g. Marfan syndrome), due to 
other causes (e.g. aortitis), and patients with malignant 
disease were excluded.
tissue and blood sampling
Full thickness wall biopsies were collected, one part 
frozen in liquid nitrogen for RNA analysis, and the other 
part kept on 4% formalin for immunohistochemistry. 
Owing to shortage of tissue materials, not all analyses were 
P
rotected by copyright.















3Holt M, et al. Open Heart 2019;6:e001098. doi:10.1136/openhrt-2019-001098
Aortic and vascular disease
Figure 1 Gene expression of C3aR1, C5aR1 and C5aR2 in TAA compared with controls. Gene expression of (A) C3aR 
(controls, n=13; TAA, n=28), (B) C5aR1 (controls, n=13; TAA, n=26) and (C) C5aR2 (controls, n=12; TAA, n=27) in aortic 
tissue from controls versus TAA. Gene expression was normalised to the reference gene EIFβ2. Data are shown as individual 
measurements with mean (horizontal line) and SEM (error bars). P values were determined by Mann- Whitney U test. TAA, 
thoracic aortic aneurysm.
performed in all individuals. Preoperative arterial blood 
samples were collected in sterile EDTA tubes, placed 
on melting ice, centrifuged within 30 min at 2000×g for 
20 min to obtain platelet- poor plasma, before storing 
in multiple aliquots at −80°C. Samples for complement 
analyses were thawed only once.
Immunohistochemistry
Formalin fixed, paraffin- embedded 5 µm thick sections 
were deparaffinised and rehydrated, blocked with 3% 
H2O2, followed by high- temperature epitope retrieval in 
citrate buffer (pH 6). Sections were rinsed in phosphate- 
buffered saline (PBS) two times and blocked with 
PBS/0.5% bovine serum albumin/0.1% Tween 20, 
before 1- hour incubation with primary antibody at room 
temperature. Slides were stained with the following 
primary antibodies; mouse anti- human smooth muscle 
α-actin (1:200, DAKO, Glostrup, Denmark), mouse 
anti- human CD68 (1:200, DAKO), rabbit anti- human 
CD3 (1:50, DAKO) and rabbit anti- human C5aR2 (1:50, 
Abcam, Cambridge, UK) (online supplementary material 
table S1). After washing in PBS, slides were incubated for 
1 hour with peroxidase- conjugated anti- mouse and anti- 
rabbit secondary antibodies (online supplementary mate-
rial table S2), both from ImmPRESS (Burlingame, CA). 
3,3′-diaminobenzidine (DAB) kit (SK-4100, ImmPRESS) 
was used for visualisation. To ensure specific staining, 
a staining without primary antibody was carried out 
and served as a negative control. Stained sections were 
scanned and uploaded to  z9. nird. sigma2. no, an in- house 
made application for evaluation and quantitative exam-
ination of histological sections. Areal positive staining 
for smooth muscle α-actin, CD3, CD68 and C5aR2 in the 
aortic media was quantified relative to total tissue area, 
based on colorimetric thresholding of the DAB staining 
in the HSV colour space.
Immunofluorescence
Formalin fixed, paraffin- embedded 5 µm thick sections 
were deparaffinised and rehydrated, blocked with 
BLOXALL (SP-6000, Vector labs, Burlingame, Cali-
fornia, USA) and treated with citrate buffer (pH 6) to 
retrieve epitopes. Sections were rinsed in tris buffered 
saline with 0.1% Tween 20 (TBST) two times, blocked 
with 2.5% normal goat serum plus 2.5% normal horse 
serum (S-1012 and S-2012, Vector labs), and incubated 
with the following primary antibodies; rat anti- mouse/
human Mac-2 (1:600, Cedarlane, Burlington, Canada), 
rabbit anti- human αSMA (1:200, Abcam) and rabbit 
anti- human CD3 (1:50, Abcam) at room temperature 
for 1 hour. Rat- on- mouse AP- Polymer (RT518H, Biocare 
Medical, Pacheco, California, USA) was used for sections 
stained with anti- Mac-2, according to manufacturer’s 
recommendations. ImmPRESS AP reagent kit (anti- 
rabbit, MP-5401) was used for sections stained with anti-
αSMA and anti- CD3, according to manufacturer’s recom-
mendations.
For visualisation, ImmPACT Vector Red- kit (SK-5105, 
Vector labs) was used, according to manufacturer’s 
recommendations. Sections were further treated with 
citrate buffer for 10 min, blocked with 2.5% normal goat 
serum for 30 min at room temperature and incubated 
with rabbit anti- human C5aR2 (1:20, Abcam) overnight 
at 4°C. Sections were rinsed in three changes of PBS and 
incubated with anti- rabbit Alexa Fluor 488 secondary 
antibodies (1:500, Invitrogen, Eugene, Oregon, USA) 
at room temperature for 1 hour. To ensure specific 
staining, staining without primary antibody was carried 
out and served as a negative control. Nuclei were coun-
terstained with 4′,6- diamidino-2- phenylindole (DAPI) in 
a mounting solution (P36931 ProLong Gold Antifade 
Mountant with DAPI, Invitrogen). To assess which cell 
types C5aR2 colocalised with, sections were evaluated 
in a qualitative manner by a blinded observer. Images 
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Figure 2 Immunostaining of C5aR2, αSMA, CD3 and CD68 in aortic media of TAA patients compared with controls. Amount 
of positive immunostaining of (A) C5aR2 (controls, n=12; TAA, n=27), (B) αSMA (controls, n=13; TAA, n=28), (C) CD3 (controls, 
n=12; TAA, n=20) and (D) CD68 (controls, n=14; TAA, n=24) in aortic media of controls versus TAA. Data are shown as individual 
measurements with mean (horizontal line) and SEM (error bars). Representative images of different sections from TAA are 
shown in the lower panels. TAA, thoracic aortic aneurysm.
were obtained using a Zeiss LSM710 confocal micro-
scope (63×1.4 plan- apochromat objective, single plane) 
(Oberkochen, Germany). Images were analysed by Zeiss 
software.
mRnA quantification
Total RNA was extracted from aortic tissue using RNeasy 
Mini Columns (QIAGEN, Hilden, Germany), RNA was 
reverse- transcribed to cDNA by using the qScript cDNA 
SuperMix (Quanta BioSciences, Beverly, Massachusetts, 
USA). Reverse transcription of RNA was performed with 
GeneAmp PCR System 9700 (Applied Biosystems, Foster 
By, California, USA), and cDNA was stored at –20°C. 
Quantification of gene expression was performed in 
duplicate by quantitative real- time PCR using Taqman 
probes (See online supplementary material table S3). 
Gene expression was normalised against EIF2β1, a gene 
highly suitable for TAA materials,20 and relative gene 
expression calculated using the 2-ΔΔCt- method.
P
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enzyme-linked immunosorbent assay
ELISA used to quantify C3bc and soluble terminal comple-
ment complex (TCC/C5b-9) in plasma was performed as 
described by Bergseth et al.21
statistical analysis
GraphPad Prism V.7.0 software (GraphPad Software, 
San Diego, California, USA) was used for data analysis. 
Comparison between two groups of individuals was 
performed using Mann- Whitney U test to compare ranks. 
ROUT outlier test, which is a robust test for defining and 
excluding outlieres,22 (Q=0.1%) was used to remove defi-
nite outliers. Patient characteristics were analysed using 
IBM SPSS Statistics V.24 (IBM, Armonk, New York, USA). 
t- Test was used for comparisons of continuous variables 
and Fisher’s exact test for statistical analysis of categor-
ical variables. Data are shown in graphs as mean±SEM. A 
p value below 0.05 (two- sided) was considered statistical 
significant.
Results
Gene expression of C5aR2 is downregulated in thoracic aortic 
aneurysms
We first investigated the gene expression of the three 
complement anaphylatoxin receptors, C3aR1, C5aR1 and 
C5aR2, in patients with ascending TAA (n=28) compared 
with controls (n=13). Whereas there was no difference 
in mRNA levels of C5aR1 (p=0.87) or C3aR (p=0.09) 
between the two patient groups (figure 1A,B), mRNA 
levels of C5aR2 was markedly decreased in TAA compared 
with controls (figure 1C, 73% decrease, p=0.005).
lower aortic protein levels of C5aR2 in patients with tAA
Immunostaining revealed C5aR2 staining in the aortic 
media, aortic adventitia and aortic plaques, with lower 
levels of C5aR2 in TAA, as compared with controls 
(figure 2A, p=0.031). Also, levels of αSMA expressing 
cells in the aortic media of TAA patients were lower 
compared with controls (figure 2B, p<0.001). In contrast, 
although there were large inter- individual differences, 
there were no differences between the two groups in 
relation to amount of T- cells (CD3- expressing cells) or 
macrophages (CD68 expressing cells) in the aortic media 
(figure 2C,D).
C5aR2 colocalised with t cells and macrophages in the media 
of patients with tAA
We selected sections from five TAA patients and five 
controls for immunofluorescence staining, to visualise 
to which cells C5aR2 colocalised in the aortic wall. 
C5aR2 showed a clear intracellular colocalisation with 
macrophages (Mac-2) and T cells (CD3) within the aortic 
wall of TAA patients and controls (figure 3).
no systemic complement system activation in patients with 
tAA
Finally, we examined systemic complement activation by 
measuring C3bc and sC5b-9 in the two groups (controls 
n=29, TAA n=23). There were no differences in systemic 
complement activation in the two groups, C3bc (p=0.054) 
and sC5b-9 levels (p=0.34), and most of the values were 
within normal limits (figure 4).
dIsCussIOn
In the present study we observed a strikingly specific and 
substantial reduction in the expression of the comple-
ment receptor C5aR2, known to signal mainly anti- 
inflammatory,17 18 in the aortic wall of TAA. This is, to 
the best of our knowledge, the first time an imbalance 
in the expression of the complement receptors has been 
documented in TAA. Given that C5a is important in the 
pathogenesis of TAA, the reduced expression of C5aR2 
combined with a fully preserved C5aR1 expression, might 
diverge the response into an enhanced inflammatory 
state, since the C5a- C5aR1 axis is a very potent proinflam-
matory signalling system.
It is not fully understood what causes dilatation of the 
thoracic aorta, but there is increasing evidence for the 
role of chronic inflammation in TAA.23 The complement 
system is an important arm of the innate immune system, 
and is capable of producing both local and systemic 
inflammation. A role of complement in AAA has been 
suggested in various studies,19 24 whereas the impact of 
complement in TAA is not clear. In this study we investi-
gated the expression of complement anaphylatoxin recep-
tors in human TAA. We found a markedly decreased gene 
and protein expression of C5aR2 in TAA as compared 
with non- aneurysmatic atherosclerotic aortas, without 
any differences in C3aR and C5aR1 between the two 
groups. This highly specific C5aR2 reduction is clearly of 
interest. Although the function of C5aR2 is still contro-
versial and the functional consequences of downregula-
tion of this receptor in human TAA are at present not 
clear, there are increasing evidence that C5aR2 is mainly 
an anti- inflammatory signalling receptor.17 18 Our data 
could therefore indicate an increased inflammatory load 
in TAA involving complement activation as potential 
mediator.
There are a few other studies on complement recep-
tors in thoracic aortic dilatation and dissection. Ren 
et al has reported systemic complement activation and 
upregulation of C3aR in human TAA suggesting that the 
C3a- C3aR1 axis promotes TAA rupture.25 However, their 
control groups consisted of plasma from healthy volun-
teers and aortic tissue from patients undergoing heart 
transplantation without any additional information on 
the presence of atherosclerosis. Moreover, the samples 
were taken during dissection just prior to rupture. It is 
not inconceivable that the complement system is more 
activated during dissection as compared with the chronic 
phase of aortic dilatation.
The role of the C5a- C5aR2 axis in TAA has not previ-
ously described. As mentioned, the role of C5aR2 is still 
controversial. In experimental models of allergic contact 
dermatitis and LPS and immune complex induced lung 
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Figure 3 C5aR2 colocalised with T cells and macrophages in the media of patients with TAA. Immunofluorescence staining 
of (A) C5aR2 and αSMA, (B) C5aR2 and CD3, (C) C5aR2 and Mac-2. C5aR2 showed a clear intracellular colocalisation with 
(B) T cells (CD3) within the aortic wall and (C) macrophages (Mac-2). There was no colocalisation with (A) smooth muscle cells. 
Representative images of immunofluorescence different sections from aortic wall are shown. TAA, thoracic aortic aneurysm.
injury, C5aR2 deficiency exacerbates inflammation and 
tissue injury,26 27 whereas an opposite pattern is seen in 
experimental allergic asthma, acute colitis and sepsis, 
where depletion of C5aR2 alleviates the pathological 
symptoms and inflammation.28–30 In atherosclerosis, 
however, C5aR2 seems to have inflammatory properties. 
Vijayan et al has shown that in advanced human athero-
sclerotic plaques high expression of C5aR2 correlates 
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Figure 4 Plasma levels of complement activation products C3bc and sC5b-9 in patients with TAA patients compared with 
controls. Amount of (A) C3bc (controls, n=29; TAA, n=23) and (B) sC5b-9 (controls, n=29; TAA, n=22) in plasma in controls 
versus TAA. Data show individual measurements with mean (horizontal line) and SEM (error bars). P values were determined by 
Mann- Whitney U test. The dotted line represents the upper normal threshold values, C3bc: 9 CAU/mL, sC5b-9: 0.7 CAU/mL.21 
TAA, thoracic aortic aneurysm.
with high levels of inflammatory cytokines.31 In apoli-
poprotein E- deficient mice Selle et al has demonstrated 
an atheroprotective role of C5aR2 deficiency.32 Given 
the differences between AAA and TAA, and not least 
between atherosclerosis and TAA, these data should be 
interpreted with great caution with respect to their rele-
vance for the pathophysiology of TAA.
Cystic medial degeneration with loss of smooth muscle 
cells is a histological hallmark of TAA which is also seen in 
the present study.33 He et al described the inflammatory 
infiltrate in aneurysmal thoracic aorta, which contains 
CD3+ and CD68+ cells,34 and a similar pattern was also 
found in the media of TAA patients in our material. 
However, the immune cell infiltration did not differ from 
samples obtained from non- aneurysmatic atherosclerotic 
thoracic aortas, underscoring the need for appropriate 
controls when studying non- syndromic TAA. Interest-
ingly, however, C5aR2 in media of TAA patients were 
colocalised with T cells and macrophages showing intra-
cellular localisation in both cell types, as also have been 
reported by others in others in various tissues.35 Verghese 
et al have recently reported that C5aR2 augment the acti-
vation of regulatory T cells promoting cardiac allograft 
survival in an experimental mouse model, supporting an 
anti- inflammatory role of C5aR2 also within the T cell 
population.36 Finally, and most importantly, our colocal-
isation data suggest that the downregulation of C5aR2 
in TAA does not merely reflect downregulation of the 
C5aR2 expressing cells (i.e. T cells and macrophages).
We have included patients from the largest depart-
ment of cardiothoracic surgery in Norway, and the popu-
lation is a relevant TAA- group regarding gender, age 
and important aortic size determinants such as weight 
and height in comparison to other TAA cohorts.37 
However, there are some important limitations of the 
current study. Our study population was relatively small 
and all patients were selected from a patient population 
that was electively operated at the lower, recommended 
aortic diameter.38 The data could therefore not without 
limitations be interpreted as representative for more 
advanced TAA including those undergoing dissection 
and rupture.
In conclusion, our findings document downregulation 
of C5aR2 in electively operated TAA as compared with 
non- aneurysmatic aortas, from patients undergoing AVR 
and/or CABG. Although the function of C5aR2 is still 
under debate, the recent data pointing to this receptor 
as an anti- inflammatory receptor indicate that the func-
tional consequences of C5aR2 downregulation in TAA 
may enhance the inflammatory effects induced by C5aR1, 
which was preserved in the TAA lesion.
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